ScreenerHero

CLDXCelldex Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · celldex.com
40.38USD-3.17%Mkt Cap: 3.17B $P/E: —

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap3.17B $
Enterprise Value2.42B $
Revenue (TTM)158.00K $
Gross Profit-278.65M $
Net Income (TTM)-258.76M $
Revenue/Share0.0020 USD
Last Price40.38 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees198
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-9.60
PEG—
EV/EBITDA-7.52
EV/Revenue15340.42
P/S19851.07
P/B4.39
EPS (TTM)-4.17
EPS (Forward)-4.16
52W Range
20.3781% of range45.14
52W High45.14 USD
52W Low20.37 USD
Profitability
Gross Margin0.00%
Oper. Margin-366468.20%
EBITDA Margin0.00%
Profit Margin-16748.03%
ROE-49.08%
ROA-44.38%
Growth
Revenue Growth-97.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-210.94M $
CapEx (TTM)2.71M $
FCF Margin-84228.16%
FCF Yield-4.20%
Net Debt-712.68M $
Net Debt/EBITDA2.21
Balance Sheet
Debt/Equity0.00
Current Ratio11.82
Quick Ratio11.71
Book Value/Sh9.103 USD
Cash/Share9.138 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateFeb 11, 2019
Splits
Last Split1:15
Split DateFeb 11, 2019
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)58.07 USD
Upside (mean)+43.8%
Target Range38.00 USD – 100.00 USD
$38.00+43.8% to mean$100.00
# Analysts15
Ownership
Shares Out.78.53M
Float73.02M
Insiders0.27%
Institutions110.31%
Short Interest
Short Ratio7.5d
Short % Float11.53%
Short % Out.9.71%
Shares Short7.63M
Short (prev mo.)7.74M
Technical
SMA 5037.31 (+8.2%)
SMA 20030.69 (+31.6%)
Beta0.84
S&P 52W Chg18.16%
Avg Vol (30d)896.68K
Avg Vol (10d)944.24K
Technical Indicators
RSI (14)53.6
MACD1.5912
MACD Signal1.7247
MACD Hist.-0.1336
BB Upper45.96 USD
BB Middle39.89 USD
BB Lower33.82 USD
BB Width30.44%
ATR (14)1.702 USD
Vol Ratio (20d)0.82x